There have been no adverse functions or improvements from baseline in serologic studies and crucial signs in any in the contributors. The treatment's discomfort-relieving results have been confirmed by way of common, 12-week follow-ups, confirming the safety and performance of BTX-A on Continual ON and suggesting that this method is a good, novel d